Eupraxia Pharmaceuticals, Inc. (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc. has set the price for its $30 million public offering at C$4.10 per share, issuing 7,317,000 shares with Raymond James Ltd. as the sole underwriter. The company plans to use the proceeds for R&D, general expenses, and other corporate purposes, with the offering expected to close by March 15, 2024. An over-allotment option is also available for an additional 15% of shares post-offering.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
